MedTrace Logo

A Study to Evaluate ATX-898 in Participants With Advanced Solid Tumors

NCT07767474 · Status: NOT_YET_RECRUITING · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 343

Last updated 2026-08-17

No results posted yet for this study

Summary

Study ATX-898-101 is a phase 1/2 open-label study evaluating the safety, tolerability, pharmacokinetic, and preliminary efficacy of ATX-898 as monotherapy and in combination with anti-neoplastic agents in selected solid tumors. This study consists of 2 parts. Part 1 evaluates ATX-898 as monotherapy and Part 2 evaluates ATX-898 in combination with anti-neoplastic agents of interest. Both parts will consists of a dose escalation portion and a dose expansion portion.

Conditions

Interventions

DRUG

ATX-898

Doses defined per protocol

DRUG

ATX-898

RDE

DRUG

ATX-898

RDE

DRUG

ATX-898

RDE

DRUG

ATX-898

Doses defined per protocol

DRUG

ATX-898, fulvestrant, ribociclib

ATX-898 at RDE, Fulvestrant and abemaciclib: doses defined per protocol

DRUG

ATX-898, fulvestrant, ribociclib

ATX-898 at RDE, Fulvestrant and abemaciclib: doses defined per protocol

DRUG

ATX-898, fulvestrant, ribociclib

Doses defined per protocol

Sponsors & Collaborators

  • Antares Therapeutics, Inc

    lead INDUSTRY

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-08-01
Primary Completion
2028-10-28
Completion
2030-01-31
FDA Drug
Yes

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07767474 on ClinicalTrials.gov